Clinical Research Directory
Browse clinical research sites, groups, and studies.
Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02)
Sponsor: Merck Sharp & Dohme LLC
Summary
Researchers want to learn if patritumab deruxtecan (MK-1022) can treat certain gastrointestinal (GI) cancers. The GI cancers being studied are advanced (the cancer has spread to other parts of the body). The goals of this study are to learn: * About the safety and how well people tolerate of patritumab deruxtecan * How many people have the cancer respond (get smaller or go away) to treatment
Official title: A Phase 1/2 Study to Evaluate the Safety and Efficacy of Patritumab Deruxtecan in Gastrointestinal Cancers
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
180
Start Date
2024-11-03
Completion Date
2028-12-07
Last Updated
2026-03-16
Healthy Volunteers
No
Conditions
Interventions
Patritumab deruxtecan
Administered via intravenous (IV) infusion
Locations (62)
UCLA Hematology Oncology Santa Monica ( Site 1205)
Santa Monica, California, United States
University of Colorado Cancer Center ( Site 1200)
Aurora, Colorado, United States
Sibley Memorial Hospital ( Site 1208)
Washington D.C., District of Columbia, United States
University of Florida ( Site 1202)
Gainesville, Florida, United States
Mount Sinai Medical Center Comprehensive Cancer Center ( Site 1213)
Miami Beach, Florida, United States
Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital-Research ( Site 1203)
Marietta, Georgia, United States
University of Chicago Medical Center ( Site 1204)
Chicago, Illinois, United States
Renown Regional Medical Center ( Site 1221)
Reno, Nevada, United States
NYU Langone Hospital - Long Island ( Site 1230)
Mineola, New York, United States
Perlmutter NYU Cancer Center ( Site 1212)
New York, New York, United States
Scott & White Medical Center-Temple ( Site 1224)
Temple, Texas, United States
Oncology and Hematology Associates of Southwest Virginia (BRCC) ( Site 1207)
Roanoke, Virginia, United States
University of Wisconsin ( Site 1210)
Madison, Wisconsin, United States
Westmead Hospital ( Site 0100)
Sydney, New South Wales, Australia
Alfred Health ( Site 0102)
Melbourne, Victoria, Australia
Austin Health ( Site 0103)
Melbourne, Victoria, Australia
One Clinical Research ( Site 0104)
Mount Pleasant, Western Australia, Australia
QEII Health Sciences Centre - Victoria General Site ( Site 0200)
Halifax, Nova Scotia, Canada
Sunnybrook Research Institute - Odette Cancer Centre ( Site 0206)
Toronto, Ontario, Canada
McGill University Health Centre ( Site 0202)
Montreal, Quebec, Canada
Fundacion Arturo Lopez Perez ( Site 0301)
Santiago, Region M. de Santiago, Chile
Centro de Oncología de Precisión ( Site 0305)
Santiago, Region M. de Santiago, Chile
Clínica UC San Carlos de Apoquindo ( Site 0302)
Santiago, Region M. de Santiago, Chile
Bradfordhill ( Site 0300)
Santiago, Region M. de Santiago, Chile
The First Affiliated Hospital of Anhui Medical University ( Site 0405)
Hefei, Anhui, China
Fujian Provincial Cancer Hospital ( Site 0408)
Fuzhou, Fujian, China
Zhongshan Hospital Fudan University (Xiamen Branch) ( Site 0412)
Xiamen, Fujian, China
Southern Medical University Nanfang Hospital ( Site 0413)
Fuzhou, Guangdong, China
The First Affiliated Hospital, Sun Yat-sen University ( Site 0404)
Guangzhou, Guangdong, China
Affiliated Cancer Hospital of Guangxi Medical University ( Site 0411)
Nanning, Guangxi, China
Henan Cancer Hospital ( Site 0403)
Zhengzhou, Henan, China
Zhongshan Hospital,Fudan University ( Site 0400)
Shanghai, Shanghai Municipality, China
First Hospital of Shanxi Medical University ( Site 0409)
Taiyuan, Shanxi, China
Hopital de la Croix Rousse ( Site 0502)
Lyon, Auvergne-Rhône-Alpes, France
Hopital Beaujon ( Site 0500)
Clichy, Hauts-de-Seine, France
Centre Eugène Marquis Rennes - Centre de Lutte Contre le Cancer ( Site 0501)
Rennes, Ille-et-Vilaine, France
Rambam Health Care Campus ( Site 0603)
Haifa, Israel
Hadassah Medical Center ( Site 0602)
Jerusalem, Israel
Sourasky Medical Center ( Site 0601)
Tel Aviv, Israel
Fondazione IRCCS Istituto Nazionale dei Tumori ( Site 0700)
Milan, Italy
ASST Grande Ospedale Metropolitano Niguarda ( Site 0701)
Milan, Italy
Fondazione Policlinico Universitario Agostino Gemelli ( Site 0702)
Roma, Italy
Harbour Cancer & Wellness ( Site 0800)
Auckland, New Zealand
Seoul National University Hospital ( Site 0900)
Seodaemun-gu, Seoul, South Korea
Severance Hospital, Yonsei University Health System ( Site 0903)
Seoul, South Korea
Asan Medical Center ( Site 0902)
Seoul, South Korea
Samsung Medical Center ( Site 0901)
Seoul, South Korea
Hospital Central de Asturias ( Site 1001)
Oviedo, Principality of Asturias, Spain
Hospital Universitari Vall d'Hebron ( Site 1000)
Barcelona, Spain
Hospital Universitario Gregorio Maranon ( Site 1002)
Madrid, Spain
Hospital Clinico San Carlos... ( Site 1003)
Madrid, Spain
Hopitaux Universitaires de Geneve HUG. ( Site 1102)
Geneva, Switzerland
Universitaetsspital Zuerich ( Site 1105)
Zurich, Switzerland
National Cheng Kung University Hospital-Clinical Trial Center ( Site 1502)
Tainan, Taiwan
National Taiwan University Hospital ( Site 1500)
Taipei, Taiwan
Taipei Veterans General Hospital ( Site 1501)
Taipei, Taiwan
Faculty of Medicine Siriraj Hospital ( Site 1301)
Bangkoknoi, Bangkok, Thailand
Ramathibodi Hospital ( Site 1302)
Ratchathewi, Bangkok, Thailand
Dr. Abdurrahman Yurtaslan Ankara Onkoloji Egitim ve Arastırma Hastanesi ( Site 1400)
Yenimahalle, Ankara, Turkey (Türkiye)
Dokuz Eylul Universitesi Hastanesi ( Site 1402)
Balçova, İzmir, Turkey (Türkiye)
Adana City Hospital ( Site 1404)
Adana, Turkey (Türkiye)
Hacettepe Universite Hastaneleri ( Site 1401)
Ankara, Turkey (Türkiye)